A growing body of evidence suggests that activation of the glutamatergic system, particularly
N-methyl-d-aspartate (NMDA) receptor function, may be a viable approach to the treatment …

In the central nervous system, glutamate is essential for a proper synaptic communication in
neuronal networks supporting critical behavioral activities such as learning and memory …

Multiple lines of evidence suggest that a dysfunction in the glutamatergic neurotransmission
via the N-methyl-D-aspartate (NMDA) receptors contributes to the pathophysiology of …

The recent discovery of glycine transporters in both the CNS and the periphery suggests that
the glycine transporter may play a critical role in NMDA receptor function by modulating …

Current antipsychotic drugs are only partially effective in treating schizophrenia and there is
a clear need to develop better therapies. An alternative approach to develop new …

While pharmacological blockade of dopamine D2 receptor can effectively suppress the
psychotic or positive symptoms of schizophrenia, there is no satisfactory medication for the …

Modulation of neurotransmission mediated by glutamate is a novel strategy for treating
psychiatric disorders, particularly negative symptoms and cognitive deficits in schizophrenia …

While current antipsychotic medications are often efficacious for the positive symptoms of
schizophrenia, there remains a critical need for compounds with improved tolerability and …

Negative symptoms of schizophrenia are a key factor determining long-term disability
associated with this disorder. Effective treatments for these symptoms are lacking. Deficient …

Clinically utilized antipsychotic agents share as a common mechanism the ability to
antagonize dopamine D2 receptors and it is widely assumed that this activity contributes to …